ImpediMed, a company out of Carsbad, California, is releasing in the U.S. its L-Dex lymphedema assessment system. The system uses so-called bioimpedance spectroscopy to identify limb swelling sites before there are symptoms or external signs.
Bioimpedance spectroscopy uses electric signals to see the presence of extracellular fluids within biological tissues. Sending current at different frequencies across a limb can point to excessive quantities of fluids within the region. The device outputs a readout of the amount of electrical resistance after each test, letting clinicians quickly estimate the extent of build-up beneath the electrodes.
From the announcement:
An independent clinical trial conducted at Magee-Womens Hospital of UPMC between 2010 and 2013 found that BIS technology helped reduce the clinical lymphedema rate from 36.4 percent to 4.4 percent. A randomized controlled study using L-Dex is currently underway at six leading cancer centers, including the Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, Mayo Clinic, University of Kansas Cancer Center, VCU Massey Cancer Center and Macquarie University. Interim results of this study will be released in late 2016, increasing the clinical evidence that supports the vital role of BIS in early identification of lymphedema in patients being treated for breast cancer and other cancers.
Product page: L-Dex U400…
Source: ImpediMed Limited…